Review & Extracts of the Form10-Q as required by the Securities & Exchange Commission

Bodisen Biotech, Inc. (the “Company”) (OTC Pink Sheets: BBCZ; London AIM: BODI; website: www.bodisen.com) today announced its first quarter unaudited results for the period ended March 31, 2008 which are extracted from the Company’s Form 10-Q filed with the SEC.

First Quarter Financial & Operational highlights

Revenues of $900,000 compared with $5.0m in the same period of 2007.

Net Income was a profit of $1.76m compared with a loss of ($3.36m) for the same period, following a bad debt recovery of $2.1m.

Diluted EPS was $0.10 compared with ($0.08) in the same period last year.

Enquiries:

Charles Stanley Securities
Rick Thompson / Philip Davies / Freddy Crossley 020 7149 6000

Bodisen Biotech, Inc.
Scott King 001 219 939 3073

Results of Operations

Three months ended March 31, 2008 compared to Three months ended March 31, 2007.

Revenue. We generated revenues of $908,519 for the three months ended March 31, 2008, a decrease of $4,009,953, compared to $5,008,472 for the three months ended March 31, 2007. The significant decrease in revenue was due to the fact that we had a much smaller customer base in the three months ended March 31, 2008 as compared to March 31, 2007 (as a result of the loss of customers following our delisting from the American Stock Exchange, or Amex), as well as a snow storm that occurred in the first quarter of 2008, which affected crop plantings and led to a decrease in the use of fertilizer.

Gross Profit. We achieved a gross profit of $341,231 for the three months ended March 31, 2008, a decrease of $1,648,991, compared to $1,990,222 for the three months ended March 31, 2007. The significant decrease in gross profit was due to the significant decrease in sales revenue. Gross margin (gross profit as a percentage of revenues), decreased from 39.7% for the three months ended March 31, 2007, to 37.6% for the three months ended March 31, 2008, primarily as a result of a small increase in raw material costs.

Operating expenses. We incurred net operating expenses of $841,603 for the three months ended March 31, 2008, a decrease of $2,679,920 or 76.1% compared to $3,521,523 for the three months ended March 31, 2007. The significant decrease was primarily a result of the fact that operating expenses for the three months ended March 31, 2007 were higher than normal due to a $1,360,277 allowance for bad debts recorded during that period. The decrease was also due to an overall reduction in overhead due to the decrease in sales.

Aggregated selling expenses accounted for $182,259 of our operating expenses for the three months ended March 31, 2008, a decrease of $166,755 or 47.8% compared to $349,014 for the three months ended March 31, 2007. The decrease in our aggregated selling expenses is due to the significant decrease in sales. General and administrative expenses accounted for the remainder of our operating expenses of $659,344 for the three months ended March 31, 2008, which decreased $2,513,165 or 79.2% compared to $3,172,509 for the three months ended March 31, 2007. The significant decrease in general and administrative expenses was a result of the fact that such expenses for the three months ended March 31, 2007 were higher than normal due to a $1,360,277 allowance for bad debts recorded during that period. The decrease was also due to an overall reduction in overhead due to the decrease in sales..

Non Operating Income and Expenses. We had total non-operating income of $2,268,307 for the three months ended March 31, 2008 compared to total non-operating income of $21,755 for the three months ended March 31, 2007. Other income was $2,212,059 for the three months ended March 31, 2008 compared to other expense of $67,197 for three months ended March 31, 2007. The change is primarily due to a bad debt recovery of $2,184,912 during the three months ended March 31, 2008. Interest income was $56,248 for the three months ended March 31, 2008 compared to $90,009 of interest income for the three months ended March 31, 2007. The decrease in 2008 is due to a decrease in our overall cash balance.

Net Income/(loss). We had net income of $1,767,935 for the three months ended March 31, 2008 compared to a net loss of $(1,509,546) for the three months ended March 31, 2007. We had earnings/(loss) per share of $0.10 and $(0.08) for the three months ended March 31, 2008 and 2007, respectively.

About Bodisen Biotech, Inc.

Bodisen Biotech, Inc. is a leading manufacturer of liquid and organic compound fertilizers, pesticides, insecticides and agricultural raw material certified by the Petroleum Chemical Industry Administrative office of China (Chemical Petroleum Production Administrative Bureau), Shaanxi provincial government and Chinese government. The company is headquartered in Shaanxi province and is a Delaware corporation. The company files annual and periodic reports with the U.S. Securities and Exchange Commission, which are accessible at www.sec.gov.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.